

## Henry Schein Receives Sufficient Acceptances to Acquire Software of Excellence Limited

September 30, 2007

Will Establish Leading Positions in the UK, Australian and New Zealand Dental Practice Software Market

MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 30, 2007--Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today announced it has received sufficient acceptances of its offer to acquire Software of Excellence International Ltd., (NZX: SOE), for NZ\$2.90 per share. Excluding transaction costs, the total purchase price is NZ\$82.0 million (approximately \$61.4 million). Henry Schein expects the transaction to be neutral to 2007 earnings and slightly accretive to 2008 earnings. Henry Schein expects the acquisition to close shortly.

"Software of Excellence has been delivering innovative solutions to Dental professionals since 1988," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "Software of Excellence's clinical and practice management software will be an important addition to Henry Schein, supporting our objective to be a full service provider to our customers. On behalf of Team Schein, we are very happy to welcome CEO Brian Weatherly and his management team to Henry Schein."

"We look forward to joining Team Schein, an established leader in providing innovative solutions to the dental community," said Brian Weatherly, Chief Executive Officer of Software of Excellence. "Together we will be able to offer integrated solutions to our dental customers, enabling them to spend more time delivering quality care to their patients."

Henry Schein noted that it has received acceptances from Software of Excellence shareholders equal to approximately 91.9% of the voting rights of Software of Excellence and has begun the necessary process to compulsorily acquire the remaining shares.

### About Software of Excellence

Software of Excellence is a leading supplier of practice management systems to both private and public health dentists in the United Kingdom, and is also the largest supplier of dental software in Australia and New Zealand. The Company serves more than 5,000 practices in the United Kingdom, Ireland, Australia and New Zealand and had revenue from continuing operations of approximately \$19.1 million for its year ended March 31, 2007.

### About Henry Schein

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 500,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 85,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as Aruba(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices, including DENTRIX(R) and Easy Dental(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs nearly 12,000 people and has operations in 19 countries. The Company's net sales reached a record \$5.05 billion in 2006. For more information, visit the Henry Schein Web site at [www.henryschein.com](http://www.henryschein.com).

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect us; financial risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

CONTACT: Henry Schein, Inc.

Steven Paladino, 631-843-5500  
Executive Vice President and Chief Financial Officer  
steven.paladino@henryschein.com

or

Investors: Neal Goldner, 631-845-2820  
Vice President, Investor Relations  
neal.goldner@henryschein.com

or

Media: Susan Vassallo, 631-843-5562  
Vice President, Corporate Communications  
susan.vassallo@henryschein.com

SOURCE: Henry Schein, Inc.